Remove Cannabis Remove DEA Remove Extraction
article thumbnail

Intoxicating Hemp Swindle

Project CBD

13 by the San Diego/Imperial Counties Joint Labor Management Cannabis Committee made up of representatives of UFCW Local 135 , and local companies March & Ash and Embarc. What’s more, synthesized Delta-9 THC is present in many of these products, despite being prohibited in both California’s cannabis and hemp programs.

Hemp 232
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 197
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NORML Says DEA’s Newly Proposed Bulk Cultivation Rules Are “Unduly Onerous, Expensive, and Impractical”

NORML

For the second time in four years, the US Drug Enforcement Administration is proposing regulatory changes to procedures governing the federally licensed manufacture of cannabis for clinical research purposes. The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants.

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. So what gives?

DEA 98
article thumbnail

‘The Doors are Wide Open’: Denver Cannabis Company Gets DEA Approval To Expand Alzheimer’s Research

Cannabis Law Report

The Denver cannabis company MedPharm can now ramp up its research into the effects marijuana has on Alzheimer’s disease. The new DEA research license will now change that. It’s possible because of a new Schedule I Researcher License granted by the Drug Enforcement Administration. credit: CBS). credit: CBS).

DEA 105
article thumbnail

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Cannabis Law Report

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT.

DEA 96